Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Thyroid Cancers

Summary

This pilot clinical trial studies how will metformin hydrochloride works in mitigating the side effects of radioactive iodine treatment in patients with differentiated thyroid cancer. Metformin hydrochloride may reduce the metabolic activity of cancer cell and of surrounding supportive tissues.

Timeline

Start

2017-01-05

Primary completion

2020-12-29

Completion

2022-12-07

Outcome

Missed primary endpoint

Stopped (Enrollment): “Poor accrual”

registry analysis (other test); Arm I (metformin hydrochloride) vs Arm II (placebo); p = 0.404; Mean Difference (Net) 0.52 (95% CI -1.26 to 2.29); t-test, 2 sided NCT03109847 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Metformin	Small molecule	—	Oral

Indications